Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015 (2015), Article ID 425708, 13 pages
http://dx.doi.org/10.1155/2015/425708
Review Article

Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells

Department of Life and Reproduction Sciences, Biochemistry Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy

Received 9 December 2014; Revised 19 March 2015; Accepted 16 April 2015

Academic Editor: Michal Wozniak

Copyright © 2015 Ilaria Dando et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Kreso and J. Dick, “Evolution of the cancer stem cell model,” Cell Stem Cell, vol. 14, no. 3, pp. 275–291, 2014. View at Publisher · View at Google Scholar
  2. E. Vlashi and F. Pajonk, “Cancer stem cells, cancer cell plasticity and radiation therapy,” Seminars in Cancer Biology, vol. 31, pp. 28–35, 2015. View at Publisher · View at Google Scholar
  3. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Vaupel and A. Mayer, “Hypoxia in cancer: significance and impact on clinical outcome,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 225–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Höckel and P. Vaupel, “Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 266–276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. G. L. Semenza, “Hypoxia, clonal selection, and the role of HIF-1 in tumor progression,” Critical Reviews in Biochemistry and Molecular Biology, vol. 35, no. 2, pp. 71–103, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. K. L. Talks, H. Turley, K. C. Gatter et al., “The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages,” The American Journal of Pathology, vol. 157, no. 2, pp. 411–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. E. E. Bar, “Glioblastoma, cancer stem cells and hypoxia,” Brain Pathology, vol. 21, no. 2, pp. 119–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Li, S. Bao, Q. Wu et al., “Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells,” Cancer Cell, vol. 15, no. 6, pp. 501–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Bao, Q. Wu, S. Sathornsumetee et al., “Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor,” Cancer Research, vol. 66, no. 16, pp. 7843–7848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. McCord, M. Jamal, U. T. Shankavaram, F. F. Lang, K. Camphausen, and P. J. Tofilon, “Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro,” Molecular Cancer Research, vol. 7, no. 4, pp. 489–497, 2009. View at Publisher · View at Google Scholar
  13. H. Ikushima, T. Todo, Y. Ino, M. Takahashi, K. Miyazawa, and K. Miyazono, “Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors,” Cell Stem Cell, vol. 5, no. 5, pp. 504–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. V. Gustafsson, X. Zheng, T. Pereira et al., “Hypoxia requires Notch signaling to maintain the undifferentiated cell state,” Developmental Cell, vol. 9, no. 5, pp. 617–628, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. V. Salnikov, L. Liu, M. Platen et al., “Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential,” PLoS ONE, vol. 7, no. 9, Article ID e46391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Cannito, E. Novo, A. Compagnone et al., “Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells,” Carcinogenesis, vol. 29, no. 12, pp. 2267–2278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Singh and J. Settleman, “EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer,” Oncogene, vol. 29, no. 34, pp. 4741–4751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Giannoni, M. Parri, and P. Chiarugi, “EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy,” Antioxidants and Redox Signaling, vol. 16, no. 11, pp. 1248–1263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Cannito, E. Novo, L. V. Di Bonzo, C. Busletta, S. Colombatto, and M. Parola, “Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease,” Antioxidants & Redox Signaling, vol. 12, no. 12, pp. 1383–1430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Huber, N. Kraut, and H. Beug, “Molecular requirements for epithelial-mesenchymal transition during tumor progression,” Current Opinion in Cell Biology, vol. 17, no. 5, pp. 548–558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Mani, W. Guo, M. J. Liao et al., “The epithelial-mesenchymal transition generates cells with properties of stem cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. L. Hwang, M. H. Yang, M. L. Tsai et al., “SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells,” Gastroenterology, vol. 141, no. 1, pp. 279.e5–291.e5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Fang, Y. Cai, J. Liu et al., “Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal,” Oncogene, vol. 30, no. 47, pp. 4707–4720, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Wang, Y. Li, and F. H. Sarkar, “Signaling mechanism(S) of reactive oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem cells in tumor progression,” Current Stem Cell Research & Therapy, vol. 5, no. 1, pp. 74–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mohyeldin, T. Garzón-Muvdi, and A. Quiñones-Hinojosa, “Oxygen in stem cell biology: a critical component of the stem cell niche,” Cell Stem Cell, vol. 7, no. 2, pp. 150–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-C. Kim, F.-J. Cui, and Y. Kim, “Hydrogen peroxide promotes epithelial to mesenchymal transition and stemness in human malignant mesothelioma cells,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 6, pp. 3625–3630, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. M. Kim and M. Cho, “Activation of NADPH oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa cells,” Cellular Signalling, vol. 26, no. 4, pp. 784–796, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Hiraga, M. Kato, S. Miyagawa, and T. Kamata, “Nox4-derived ROS signaling contributes to TGF-beta-induced epithelial-mesenchymal transition in pancreatic cancer cells,” Anticancer Research, vol. 33, no. 10, pp. 4431–4438, 2013. View at Google Scholar · View at Scopus
  30. Y. Hu, K. He, D. Wang et al., “TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways,” Carcinogenesis, vol. 34, no. 8, pp. 1764–1772, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Shimojo, M. Akimoto, T. Hisanaga et al., “Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells,” Clinical & Experimental Metastasis, vol. 30, no. 2, pp. 143–154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Shi, Y. Zhang, J. Zheng, and J. Pan, “Reactive oxygen species in cancer stem cells,” Antioxidants & Redox Signaling, vol. 16, no. 11, pp. 1215–1228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Diehn, R. W. Cho, N. A. Lobo et al., “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” Nature, vol. 458, no. 7239, pp. 780–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Ishimoto, O. Nagano, T. Yae et al., “CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth,” Cancer Cell, vol. 19, no. 3, pp. 387–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. C. J. Lin, C. C. Lee, Y. L. Shih et al., “Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells,” PLoS ONE, vol. 7, no. 6, Article ID e38706, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Pasto, C. Bellio, G. Pilotto et al., “Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation,” Oncotarget, vol. 5, pp. 4305–4319, 2014. View at Google Scholar
  37. C. I. Kobayashi and T. Suda, “Regulation of reactive oxygen species in stem cells and cancer stem cells,” Journal of Cellular Physiology, vol. 227, no. 2, pp. 421–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Y.-Y. Jang and S. J. Sharkis, “A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche,” Blood, vol. 110, no. 8, pp. 3056–3063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. T.-W. Kim, M. Michniewicz, D. C. Bergmann, and Z.-Y. Wang, “Brassinosteroid regulates stomatal development by GSK3-mediated inhibition of a MAPK pathway,” Nature, vol. 482, no. 7385, pp. 419–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Sayama, Y. Hanakawa, H. Nagai et al., “Transforming growth factor-β-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis,” The Journal of Biological Chemistry, vol. 281, no. 31, pp. 22013–22020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. L. New and J. Han, “The p38 MAP kinase pathway and its biological function,” Trends in Cardiovascular Medicine, vol. 8, no. 5, pp. 220–228, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. H. K. Koul, M. Pal, and S. Koul, “Role of p38 MAP kinase signal transduction in solid tumors,” Genes and Cancer, vol. 4, no. 9-10, pp. 342–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Dolado, A. Swat, N. Ajenjo, G. De Vita, A. Cuadrado, and A. R. Nebreda, “p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis,” Cancer Cell, vol. 11, no. 2, pp. 191–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Sato, M. Okada, K. Shibuya et al., “Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells,” Stem Cell Research, vol. 12, no. 1, pp. 119–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. G. P. George and R. D. Mittal, “MicroRNAs: potential biomarkers in cancer,” Indian Journal of Clinical Biochemistry, vol. 25, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. U. Burk, J. Schubert, U. Wellner et al., “A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells,” EMBO Reports, vol. 9, no. 6, pp. 582–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Korpal, E. S. Lee, G. Hu, and Y. Kang, “The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2,” The Journal of Biological Chemistry, vol. 283, no. 22, pp. 14910–14914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Shimono, M. Zabala, R. W. Cho et al., “Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells,” Cell, vol. 138, no. 3, pp. 592–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Mateescu, L. Batista, M. Cardon et al., “miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response,” Nature Medicine, vol. 17, no. 12, pp. 1627–1635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Vasillou, A. Pappa, and T. Estey, “Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism,” Drug Metabolism Reviews, vol. 36, no. 2, pp. 279–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Chen, G. Mehta, and V. Vasiliou, “Antioxidant defenses in the ocular surface,” The Ocular Surface, vol. 7, no. 4, pp. 176–185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. A. T. Jacobs and L. J. Marnett, “Systems analysis of protein modification and cellular responses induced by electrophile stress,” Accounts of Chemical Research, vol. 43, no. 5, pp. 673–683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. G.-P. Voulgaridou, I. Anestopoulos, R. Franco, M. I. Panayiotidis, and A. Pappa, “DNA damage induced by endogenous aldehydes: current state of knowledge,” Mutation Research, vol. 711, no. 1-2, pp. 13–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Yin, L. Xu, and N. A. Porter, “Free radical lipid peroxidation: mechanisms and analysis,” Chemical Reviews, vol. 111, no. 10, pp. 5944–5972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. E. H. Huang, M. J. Hynes, T. Zhang et al., “Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis,” Cancer Research, vol. 69, no. 8, pp. 3382–3389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Muzio, M. Maggiora, E. Paiuzzi, M. Oraldi, and R. A. Canuto, “Aldehyde dehydrogenases and cell proliferation,” Free Radical Biology & Medicine, vol. 52, no. 4, pp. 735–746, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Emadi, R. J. Jones, and R. A. Brodsky, “Cyclophosphamide and cancer: golden anniversary,” Nature Reviews. Clinical Oncology, vol. 6, no. 11, pp. 638–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. C. N. Landen Jr., B. Goodman, A. A. Katre et al., “Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer,” Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3186–3199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Wang, Y. Sun, J. Wong, and D. S. Conklin, “PPARγ maintains ERBB2-positive breast cancer stem cells,” Oncogene, vol. 32, no. 49, pp. 5512–5521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Kourtidis, R. Jain, R. D. Carkner, C. Eifert, M. J. Brosnan, and D. S. Conklin, “An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature,” Cancer Research, vol. 70, no. 5, pp. 1783–1792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Raha, T. R. Wilson, J. Peng et al., “The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation,” Cancer Research, vol. 74, no. 13, pp. 3579–3590, 2014. View at Publisher · View at Google Scholar
  62. T. Chiba, E. Suzuki, K. Yuki et al., “Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners,” PLoS ONE, vol. 9, no. 1, Article ID e84807, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. E. D. Pozza, M. Donadelli, C. Costanzo et al., “Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives,” Free Radical Biology and Medicine, vol. 50, no. 8, pp. 926–933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Aruffo, I. Stamenkovic, M. Melnick, C. B. Underhill, and B. Seed, “CD44 is the principal cell surface receptor for hyaluronate,” Cell, vol. 61, no. 7, pp. 1303–1313, 1990. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Ponta, L. Sherman, and P. A. Herrlich, “CD44: from adhesion molecules to signalling regulators,” Nature Reviews Molecular Cell Biology, vol. 4, no. 1, pp. 33–45, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Haegel, A. Dierich, and R. Ceredig, “CD44 in differentiated embryonic stem cells: surface expression and transcripts encoding multiple variants,” Developmental Immunology, vol. 3, no. 4, pp. 239–246, 1994. View at Publisher · View at Google Scholar · View at Scopus
  67. I. Bruns, R. P. Cadeddu, I. Brueckmann et al., “Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells,” Blood, vol. 120, no. 13, pp. 2620–2630, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Du, H. Wang, L. He et al., “CD44 is of functional importance for colorectal cancer stem cells,” Clinical Cancer Research, vol. 14, no. 21, pp. 6751–6760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Li, D. G. Heidt, P. Dalerba et al., “Identification of pancreatic cancer stem cells,” Cancer Research, vol. 67, no. 3, pp. 1030–1037, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. K. Croker, D. Goodale, J. Chu et al., “High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2236–2252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. U. Günthert, M. Hofmann, W. Rudy et al., “A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells,” Cell, vol. 65, no. 1, pp. 13–24, 1991. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Seiter, R. Arch, S. Reber et al., “Prevention of tumor metastasis formation by anti-variant CD44,” The Journal of Experimental Medicine, vol. 177, no. 2, pp. 443–455, 1993. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Dalla Pozza, I. Dando, G. Biondani et al., “Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bidirectionally convert into cancer stem cells,” International Journal of Oncology, vol. 46, pp. 1099–1108, 2015. View at Publisher · View at Google Scholar
  75. M. Zöller, “CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?” Nature Reviews Cancer, vol. 11, no. 4, pp. 254–267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. P. V. Pham, N. L. C. Phan, N. T. Nguyen et al., “Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy,” Journal of Translational Medicine, vol. 9, no. 1, article 209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Liu, K. Kelnar, B. Liu et al., “The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,” Nature Medicine, vol. 17, no. 2, pp. 211–216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Ohata, T. Ishiguro, Y. Aihara et al., “Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells,” Cancer Research, vol. 72, no. 19, pp. 5101–5110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Boccaccio and P. M. Comoglio, “Invasive growth: a MET-driven genetic programme for cancer and stem cells,” Nature Reviews Cancer, vol. 6, no. 8, pp. 637–645, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Lin, P. Hung, and Y. Chen, “CD44 is associated with the aggressive phenotype of nasopharyngeal carcinoma through redox regulation,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13266–13281, 2013. View at Publisher · View at Google Scholar
  81. L. Gammon, A. Biddle, H. K. Heywood, A. C. Johannessen, and I. C. Mackenzie, “Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism,” PLoS ONE, vol. 8, no. 4, Article ID e62493, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. M. P. Ween, M. K. Oehler, and C. Ricciardelli, “Role of versican, hyaluronan and CD44 in ovarian cancer metastasis,” International Journal of Molecular Sciences, vol. 12, no. 2, pp. 1009–1029, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Contreras-Ruiz, M. de la Fuente, J. E. Párraga et al., “Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells,” Molecular Vision, vol. 17, pp. 279–290, 2011. View at Google Scholar · View at Scopus
  84. H. Zhao, T. Tanaka, V. Mitlitski, J. Heeter, E. A. Balazs, and Z. Darzynkiewicz, “Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells,” International Journal of Oncology, vol. 32, no. 6, pp. 1159–1167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. V. Grishko, M. Xu, R. Ho et al., “Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes,” The Journal of Biological Chemistry, vol. 284, no. 14, pp. 9132–9139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Yae, K. Tsuchihashi, T. Ishimoto et al., “Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell,” Nature Communications, vol. 3, article 883, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Hashida, A. Takabayashi, M. Kanai et al., “Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer,” Gastroenterology, vol. 122, no. 2, pp. 376–386, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Menrad, D. Speicher, J. Wacker, and M. Herlyn, “Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells,” Cancer Research, vol. 53, no. 6, pp. 1450–1455, 1993. View at Google Scholar · View at Scopus
  89. Y. Mishima, Y. Matsumoto-Mishima, Y. Terui et al., “Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells,” Journal of the National Cancer Institute, vol. 94, no. 13, pp. 1020–1028, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Petrovic, W. Schacke, J. R. Gahagan et al., “CD13/APN regulates endothelial invasion and filopodia formation,” Blood, vol. 110, no. 1, pp. 142–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Haraguchi, H. Ishii, K. Mimori et al., “CD13 is a therapeutic target in human liver cancer stem cells,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3326–3339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Zhou, J. D. Schuetz, K. D. Bunting et al., “The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,” Nature Medicine, vol. 7, no. 9, pp. 1028–1034, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Zhou, J. J. Morris, Y. Barnes, L. Lan, J. D. Schuetz, and B. P. Sorrentino, “Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12339–12344, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. Z. Benderra, A.-M. Faussat, L. Sayada et al., “Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias,” Clinical Cancer Research, vol. 10, no. 23, pp. 7896–7902, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Kamiyama, S. Takagi, C. Yamamoto et al., “Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone,” Anticancer Research, vol. 26, no. 2, pp. 885–888, 2006. View at Google Scholar · View at Scopus
  97. S. Tsunoda, T. Okumura, T. Ito et al., “ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma,” Oncology, vol. 71, no. 3-4, pp. 251–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Zhang, Z. Wang, W. Luo, H. Jiao, J. Wu, and C. Jiang, “Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma,” Gastroenterology Research and Practice, vol. 2013, Article ID 782581, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Yang, D. Liao, C. Chen et al., “Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway,” Stem Cells, vol. 31, no. 2, pp. 248–258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Zhou, F. Chen, J. Xiao et al., “Enhanced functional properties of corneal epithelial cells by coculture with embryonic stem cells via the integrin β1-FAK-PI3K/Akt pathway,” The International Journal of Biochemistry & Cell Biology, vol. 43, no. 8, pp. 1168–1177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Krishnamurthy, D. D. Ross, T. Nakanishi et al., “The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme,” The Journal of Biological Chemistry, vol. 279, no. 23, pp. 24218–24225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Krishnamurthy, T. Xie, and J. D. Schuetz, “The role of transporters in cellular heme and porphyrin homeostasis,” Pharmacology & Therapeutics, vol. 114, no. 3, pp. 345–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Shen, D. Callaghan, C. Juzwik, H. Xiong, P. Huang, and W. Zhang, “ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease,” Journal of Neurochemistry, vol. 114, no. 6, pp. 1590–1604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. H. M. Brechbuhl, N. Gould, R. Kachadourian, W. R. Riekhof, D. R. Voelkerand, and B. J. Day, “Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2,” The Journal of Biological Chemistry, vol. 285, no. 22, pp. 16582–16587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. C. T. Supuran, “Carbonic anhydrases: novel therapeutic applications for inhibitors and activators,” Nature Reviews Drug Discovery, vol. 7, no. 2, pp. 168–181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Svastova, N. Zilka, M. Zat'ovicova et al., “Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin,” Experimental Cell Research, vol. 290, no. 2, pp. 332–345, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. P. Swietach, A. Hulikova, R. D. Vaughan-Jones, and A. L. Harris, “New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation,” Oncogene, vol. 29, no. 50, pp. 6509–6521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Lou, P. C. McDonald, A. Oloumi et al., “Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors,” Cancer Research, vol. 71, no. 9, pp. 3364–3376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. F. E. Lock, P. C. McDonald, Y. Lou et al., “Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche,” Oncogene, vol. 32, no. 44, pp. 5210–5219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. F. Pacchiano, F. Carta, P. C. McDonald et al., “Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis,” Journal of Medicinal Chemistry, vol. 54, no. 6, pp. 1896–1902, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. N. Touisni, A. Maresca, P. C. McDonald et al., “Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors,” Journal of Medicinal Chemistry, vol. 54, no. 24, pp. 8271–8277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. C. Liu and D. G. Tang, “MicroRNA regulation of cancer stem cells,” Cancer Research, vol. 71, no. 18, pp. 5950–5954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. C.-J. Chang, C.-C. Hsu, C.-H. Chang et al., “Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer,” Oncology Reports, vol. 26, no. 4, pp. 1003–1010, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. Y. Li, T. G. Vandenboom II, D. Kong et al., “Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells,” Cancer Research, vol. 69, no. 16, pp. 6704–6712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. M. F. McCarty, “Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression,” Medical Hypotheses, vol. 78, no. 2, pp. 262–269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. A. D. Saleh, J. E. Savage, L. Cao et al., “Cellular stress induced alterations in microrna let-7a and let-7b expression are dependent on p53,” PLoS ONE, vol. 6, no. 10, Article ID e24429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. P. Olson, J. Lu, H. Zhang et al., “MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer,” Genes & Development, vol. 23, no. 18, pp. 2152–2165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “microRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Dillhoff, J. Liu, W. Frankel, C. Croce, and M. Bloomston, “MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival,” Journal of Gastrointestinal Surgery, vol. 12, no. 12, pp. 2171–2176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. A. F. Golestaneh, A. Atashi, L. Langroudi, A. Shafiee, N. Ghaemi, and M. Soleimani, “MiRNAs expressed differently in cancer stem cells and cancer cells of human gastric cancer cell line MKN-45,” Cell Biochemistry and Function, vol. 30, no. 5, pp. 411–418, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Han, Y. Wang, M. Liu et al., “MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells,” Cancer Science, vol. 103, no. 6, pp. 1058–1064, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Mathé, G. H. Nguyen, N. Funamizu et al., “Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide,” International Journal of Cancer, vol. 131, no. 3, pp. 760–765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Thulasingam, C. Massilamany, A. Gangaplara et al., “miR-27b, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells,” Molecular and Cellular Biochemistry, vol. 352, no. 1-2, pp. 181–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. B. Bao, A. Ahmad, D. Kong et al., “Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF,” PLoS ONE, vol. 7, no. 8, Article ID e43726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. B. Bao, S. Ali, A. Ahmad et al., “Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment,” PLoS ONE, vol. 7, no. 12, Article ID e50165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. X. Zhang, W.-L. Ng, P. Wang et al., “MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα,” Cancer Research, vol. 72, no. 18, pp. 4707–4713, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. F. Guessous, Y. Zhang, A. Kofman et al., “microRNA-34a is tumor suppressive in brain tumors and glioma stem cells,” Cell Cycle, vol. 9, no. 6, pp. 1031–1036, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. O. A. Kent, M. Mullendore, E. A. Wentzel et al., “A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells,” Cancer Biology & Therapy, vol. 8, no. 21, pp. 2013–2024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. D. Lodygin, V. Tarasov, A. Epanchintsev et al., “Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer,” Cell Cycle, vol. 7, no. 16, pp. 2591–2600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Kong, E. Heath, W. Chen et al., “Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment,” American Journal of Translational Research, vol. 4, no. 1, pp. 14–23, 2012. View at Google Scholar · View at Scopus
  131. S. Roy, E. Levi, A. P. Majumdar, and F. H. Sarkar, “Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF,” Journal of Hematology & Oncology, vol. 5, article 58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. M. M. Aranha, D. M. Santos, S. Sola, C. J. Steer, and C. M. Rodrigues, “miR-34a regulates mouse neural stem cell differentiation,” PLoS ONE, vol. 6, no. 8, Article ID e21396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. Guo, S. Li, J. Qu et al., “MiR-34a inhibits lymphatic metastasis potential of mouse hepatoma cells,” Molecular and Cellular Biochemistry, vol. 354, no. 1-2, pp. 275–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. X. Wang, C. Meyers, M. Guo, and Z.-M. Zheng, “Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway,” International Journal of Cancer, vol. 129, no. 6, pp. 1362–1372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. D. Nalls, S.-N. Tang, M. Rodova, R. K. Srivastava, and S. Shankar, “Targeting epigenetic regulation of mir-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells,” PLoS ONE, vol. 6, no. 8, Article ID e24099, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. L. Sun, Z. Wu, Y. Shao et al., “MicroRNA-34a suppresses cell proliferation and induces apoptosis in U87 glioma stem cells,” Technology in Cancer Research & Treatment, vol. 11, no. 5, pp. 483–490, 2012. View at Google Scholar · View at Scopus
  137. K. K. Dutta, Y. Zhong, Y.-T. Liu et al., “Association of microRNA-34a overexpression with proliferation is cell type-dependent,” Cancer Science, vol. 98, no. 12, pp. 1845–1852, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Pavlides, A. Tsirigos, G. Migneco et al., “The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism,” Cell Cycle, vol. 9, no. 17, pp. 3485–3505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. X. Y. Bai, Y. Ma, R. Ding, B. Fu, S. Shi, and X. M. Chen, “miR-335 and miR-34a promote renal senescence by suppressing mitochondrial antioxidative enzymes,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1252–1261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. Y. Pang, C. Y. F. Young, and H. Yuan, “MicroRNAs and prostate cancer,” Acta Biochimica et Biophysica Sinica, vol. 42, no. 6, pp. 363–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. D. Bhaumik, G. K. Scott, S. Schokrpur, C. K. Patil, J. Campisi, and C. C. Benz, “Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells,” Oncogene, vol. 27, no. 42, pp. 5643–5647, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Liu, T. Sakamaki, M. C. Casimiro et al., “The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion,” Cancer Research, vol. 70, no. 24, pp. 10464–10473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. Y. Li, T. G. VandenBoom II, Z. Wang et al., “MiR-146a suppresses invasion of pancreatic cancer cells,” Cancer Research, vol. 70, no. 4, pp. 1486–1495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. T. Chen, Z. Huang, L. Wang et al., “MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages,” Cardiovascular Research, vol. 83, no. 1, pp. 131–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. A. I. Pogue, M. E. Percy, J.-G. Cui et al., “Up-regulation of NF-κB-sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures,” Journal of Inorganic Biochemistry, vol. 105, no. 11, pp. 1434–1437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. P. A. Gregory, A. G. Bert, E. L. Paterson et al., “The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1,” Nature Cell Biology, vol. 10, no. 5, pp. 593–601, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. M. E. Peter, “Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression,” Cell Cycle, vol. 8, no. 6, pp. 843–852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. B. Bao, Z. Wang, S. Ali et al., “Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells,” Cancer Letters, vol. 307, no. 1, pp. 26–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. D. Iliopoulos, M. Lindahl-Allen, C. Polytarchou, H. A. Hirsch, P. N. Tsichlis, and K. Struhl, “Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells,” Molecular Cell, vol. 39, no. 5, pp. 761–772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. J. A. Leal and M. E. Lleonart, “MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives,” Cancer Letters, vol. 338, no. 1, pp. 174–183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Magenta, C. Cencioni, P. Fasanaro et al., “MiR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition,” Cell Death and Differentiation, vol. 18, no. 10, pp. 1628–1639, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. T. Toyama, N. Kondo, Y. Endo et al., “High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients,” Japanese Journal of Clinical Oncology, vol. 42, no. 4, Article ID hys001, pp. 256–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. J. Wang, J. Chen, P. Chang et al., “MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease,” Cancer Prevention Research, vol. 2, no. 9, pp. 807–813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. C. Camps, F. M. Buffa, S. Colella et al., “Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1340–1348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. X. Huang, Q.-T. Le, and A. J. Giaccia, “MiR-210—micromanager of the hypoxia pathway,” Trends in Molecular Medicine, vol. 16, no. 5, pp. 230–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. M. E. Crosby, R. Kulshreshtha, M. Ivan, and P. M. Glazer, “MicroRNA regulation of DNA repair gene expression in hypoxic stress,” Cancer Research, vol. 69, no. 3, pp. 1221–1229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. H. W. Kim, H. K. Haider, S. Jiang, and M. Ashraf, “Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2,” The Journal of Biological Chemistry, vol. 284, no. 48, pp. 33161–33168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. W. Yang, T. Sun, J. Cao, F. Liu, Y. Tian, and W. Zhu, “Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro,” Experimental Cell Research, vol. 318, no. 8, pp. 944–954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. W. Yang, J. Wei, T. Guo, Y. Shen, and F. Liu, “Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance,” Experimental Cell Research, vol. 326, no. 1, pp. 22–35, 2014. View at Publisher · View at Google Scholar